{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:19:08Z","timestamp":1785482348875,"version":"3.56.0"},"reference-count":67,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>With the progressive aging of the population in industrially developed countries, as well as advances in diagnostic and biopsy techniques and improvements in patient awareness, the incidence of prostate cancer (PCa) is continuously increasing worldwide. Therefore, PCa is currently considered as the second leading cause of tumor-related death. Early detection of the tumor and its metastasis is essential, as the rate of disease recurrence is high and occurs in 27% to 53% of all patients who underwent curative therapy with radical prostatectomy or local radiotherapy. In this regard, the prostate specific membrane antigens, abbreviated as PSMAs, are type II membrane proteins that are highly expressed on the surface of malignant prostate tissue in PCa, particularly in aggressive, androgen-deprived, metastatic, and hormone-refractory PCa, and they are inversely associated with the androgen level. Up to 95% of adenocarcinomas of the prostate express PSMA receptors on their surface. Today, radionuclides that bind to these PSMA peptides are widely accepted for diagnostic and therapeutic purposes to specifically image and target prostate tumor cells at the molecular level, a process referred to as targeted theranostics. Numerous studies have demonstrated that the integration of these peptides into diagnostic and therapeutic procedures plays a critical role in the primary staging and treatment decisions of especially high-risk PCa, expands therapeutic options for patients with advanced stage of prostate tumor, and prolongs patients\u2019 survival rate. In this review article, we intend to briefly spotlight the latest clinical utilization of the PSMA-targeted radioligand PET imaging modality in patients with different stages of PCa. Furthermore, limitations and pitfalls of this diagnostic technique are presented.<\/jats:p>","DOI":"10.3390\/cancers14153768","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T21:41:37Z","timestamp":1659476497000},"page":"3768","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical Applications of PSMA PET Examination in Patients with Prostate Cancer"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2898-3232","authenticated-orcid":false,"given":"Sazan","family":"Rasul","sequence":"first","affiliation":[{"name":"Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8308-6174","authenticated-orcid":false,"given":"Alexander R.","family":"Haug","sequence":"additional","affiliation":[{"name":"Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0022-5347(01)69079-7","article-title":"Cancer control with radical prostatectomy alone in 1,000 consecutive patients","volume":"167","author":"Hull","year":"2002","journal-title":"J. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0090-4295(96)00167-7","article-title":"Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer","volume":"48","author":"Kupelian","year":"1996","journal-title":"Urology"},{"key":"ref_3","first-page":"S13","article-title":"Overview of prostate-specific membrane antigen","volume":"6","author":"Chang","year":"2004","journal-title":"Rev. Urol."},{"key":"ref_4","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/00003072-199810000-00005","article-title":"Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer","volume":"23","author":"Petronis","year":"1998","journal-title":"Clin. Nucl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Malcher","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/1078-0432.CCR-18-0768","article-title":"PSMA ligand PET\/MRI for primary prostate cancer: Staging performance and clinical impact","volume":"24","author":"Grubmuller","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00259-017-3858-2","article-title":"68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy-diagnostic performance and impact on therapeutic decision-making","volume":"45","author":"Grubmuller","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","author":"Grubmuller","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/pros.23919","article-title":"Response assessment using [68Ga] Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer","volume":"80","author":"Grubmuller","year":"2020","journal-title":"Prostate"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2967\/jnumed.119.226514","article-title":"Prospective evaluation of PSMA-targeted 18F-DCFPyL PET\/CT in men with biochemical failure after radical prostatectomy for prostate cancer","volume":"61","author":"Rowe","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2967\/jnumed.119.227793","article-title":"Prospective comparison of PET imaging with PSMA-targeted 18F-DCFPyL versus Na18F for bone lesion detection in patients with metastatic prostate cancer","volume":"61","author":"Rowe","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: Results from the CONDOR phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","article-title":"Expression of prostate-specific membrane antigen in normal and malignant human tissues","volume":"30","author":"Kinoshita","year":"2006","journal-title":"World J. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): Proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2967\/jnumed.116.172627","article-title":"68Ga-PSMA PET\/CT detects the location and extent of primary prostate cancer","volume":"57","author":"Fendler","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.eururo.2015.12.051","article-title":"68Ga-PSMA positron emission tomography\/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer","volume":"70","author":"Herlemann","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000484695","article-title":"Integrated 68gallium labelled prostate-specific membrane antigen-11 positron emission tomography\/magnetic resonance imaging enhances discriminatory power of multi-parametric prostate magnetic resonance imaging","volume":"100","author":"Grueneisen","year":"2018","journal-title":"Urol. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1148\/radiol.2018172232","article-title":"Gallium 68 PSMA-11 PET\/MR imaging in patients with intermediate-or high-risk prostate cancer","volume":"288","author":"Park","year":"2018","journal-title":"Radiology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2022.04.006","article-title":"Diagnostic performance of prostate-specific membrane antigen positron emission tomography-targeted biopsy for detection of clinically significant prostate cancer: A systematic review and meta-analysis","volume":"5","author":"Kawada","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1148\/radiol.2019190687","article-title":"Diagnostic accuracy of multiparametric MRI versus Ga-PSMA-11 PET\/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer","volume":"293","author":"Muehlematter","year":"2019","journal-title":"Radiology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13550-021-00845-z","article-title":"Intraindividual comparison of [68Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: A retrospective single-center analysis","volume":"11","author":"Hoberuck","year":"2021","journal-title":"EJNMMI Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2967\/jnumed.119.234187","article-title":"Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard","volume":"61","author":"Kuten","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","article-title":"Prospective intra-individual blinded comparison of [18F] PSMA-1007 and [68Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer","volume":"49","author":"Pattison","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(02)02411-1","article-title":"Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy","volume":"61","author":"Kane","year":"2003","journal-title":"Urology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12149-010-0390-x","article-title":"Role of 11C-choline PET\/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy","volume":"24","author":"Fuccio","year":"2010","journal-title":"Ann. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1097\/RLU.0000000000002130","article-title":"Diagnostic performance of 18F-fluciclovine in detection of prostate cancer bone metastases","volume":"43","author":"Chau","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00259-016-3329-1","article-title":"18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET\/CT in prostate cancer relapse: Results of a prospective trial","volume":"43","author":"Nanni","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J. Nucl. Med"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"684629","DOI":"10.3389\/fonc.2021.684629","article-title":"The diagnostic role of 18F-choline, 18F-fluciclovine and 18F-PSMA PET\/CT in the detection of prostate cancer with biochemical recurrence: A meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Zechmann","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","article-title":"Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients","volume":"47","author":"Vaz","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pros.22910","article-title":"Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer","volume":"75","author":"Murga","year":"2015","journal-title":"Prostate"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen","volume":"108","author":"Evans","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.116.181800","article-title":"68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: First human experience","volume":"58","author":"Hope","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3892\/ijo.2012.1649","article-title":"Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells","volume":"41","author":"Liu","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","article-title":"Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: A systematic review and meta-analysis","volume":"74","author":"Han","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00330-021-08140-0","article-title":"Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET\/MR versus PET\/CT in patients with biochemically recurrent prostate cancer","volume":"32","author":"Jentjens","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","article-title":"Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET\/CT and PET\/MRI: Comparison with mpMRI integrated in simultaneous PET\/MRI","volume":"44","author":"Freitag","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s00259-020-05082-5","article-title":"Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer","volume":"48","author":"Rasul","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12477","DOI":"10.18632\/oncotarget.7245","article-title":"Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer","volume":"7","author":"Ahmadzadehfar","year":"2016","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/1754-9485.12891","article-title":"Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution","volume":"63","author":"McBean","year":"2019","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13550-015-0114-2","article-title":"Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: A two-centre study","volume":"5","author":"Ahmadzadehfar","year":"2015","journal-title":"EJNMMI Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","article-title":"Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer","volume":"41","author":"Rahbar","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00259-019-04584-1","article-title":"Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks","volume":"47","author":"Rasul","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2967\/jnumed.119.231431","article-title":"Response prediction of 177Lu-PSMA-617 radioligand therapy using prostate-specific antigen, chromogranin A, and lactate dehydrogenase","volume":"61","author":"Rathke","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2967\/jnumed.116.178228","article-title":"Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617","volume":"58","author":"Ferdinandus","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00259-017-3877-z","article-title":"Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.7150\/thno.35759","article-title":"Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617","volume":"9","author":"Kessel","year":"2019","journal-title":"Theranostics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.120.262250","article-title":"The added value of 18F-FDG PET\/CT compared to 68Ga-PSMA PET\/CT in patients with castration-resistant prostate cancer","volume":"63","author":"Chen","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Hotta, M., Gafita, A., Czernin, J., and Calais, J. (2022). Outcome of patients with PSMA-PET\/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: A multicenter retrospective analysis. J. Nucl. Med.","DOI":"10.1200\/JCO.2022.40.16_suppl.5042"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.euo.2018.11.007","article-title":"Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy","volume":"2","author":"Thang","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2967\/jnumed.117.204677","article-title":"68Ga-PSMA-HBED-CC uptake in cervical, celiac, and sacral ganglia as an important pitfall in prostate cancer PET imaging","volume":"59","author":"Rischpler","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2967\/jnumed.119.229187","article-title":"Matched-pair comparison of 68Ga-PSMA-11 PET\/CT and 18F-PSMA-1007 PET\/CT: Frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy","volume":"61","author":"Rauscher","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2967\/jnumed.119.234898","article-title":"Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer","volume":"61","author":"Dietlein","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11934-019-0938-9","article-title":"Renal cell carcinoma: The oncologist asks, can PSMA PET\/CT answer?","volume":"20","author":"Pozzessere","year":"2019","journal-title":"Curr. Urol. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1097\/RLU.0000000000001569","article-title":"Incidental detection of head and neck squamous cell carcinoma on 68Ga-PSMA-11 PET\/CT","volume":"42","author":"Flavell","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2967\/jnumed.118.214833","article-title":"68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study","volume":"60","author":"Kesler","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2214\/AJR.19.21084","article-title":"Gallium-68\u2013labeled prostate-specific membrane antigen-11 PET\/CT of prostate and nonprostate cancers","volume":"213","author":"Osmany","year":"2019","journal-title":"Am. J. Roentgenol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/15\/3768\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:01:33Z","timestamp":1760140893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/15\/3768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":67,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["cancers14153768"],"URL":"https:\/\/doi.org\/10.3390\/cancers14153768","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]}}}